Chondroitin 6-sulfate-binding peptides improve recovery in spinal cord-injured mice

Eur J Pharmacol. 2021 Nov 5:910:174421. doi: 10.1016/j.ejphar.2021.174421. Epub 2021 Aug 12.

Abstract

The role of glycosaminoglycan sulfation patterns, particularly in regard to scar formation and inhibition of neuritogenesis, has been mainly studied in cell culture with a focus on chondroitin 4-sulfate. In this study, we investigated chondroitin 6-sulfate (C6S) and found that it also inhibits neurite outgrowth of mouse cerebellar granule neurons in vitro. To examine whether the inhibitory activity of C6S could be neutralized, seven previously characterized high-affinity C6S-binding peptides were tested, among which three peptides neutralized the inhibitory functions of C6S. We further investigated these peptides in a mouse model of spinal cord injury, since upregulation of C6S expression in the glial scar following injury has been associated with reduced axonal regrowth and functional recovery. We here subjected mice to severe compression injury at thoracic levels T7-T9, immediately followed by inserting gelfoam patches soaked in C6S-binding peptides or in a control peptide. Application of C6S-binding peptides led to functional recovery after injury and prevented fibrotic glial scar formation, as seen by decreased activation of astrocytes and microglia/macrophages. Decreased expression of several lecticans and deposition of fibronectin at the site of injury were also observed. Application of C6S-binding peptides led to axonal regrowth and inhibited the C6S-mediated activation of RhoA/ROCK and decrease of PI3K-Akt-mTOR signaling pathways. Taken together, these results indicate that treatment with C6S-binding peptides improves functional recovery in a mouse model of spinal cord injury.

Keywords: Axonal regrowth; Binding peptides; Chondroitin-6-sulfate; Lecticans; Mouse; Spinal cord injury.

MeSH terms

  • Animals
  • Axons / drug effects
  • Cells, Cultured
  • Chondroitin Sulfate Proteoglycans / metabolism
  • Chondroitin Sulfates / metabolism*
  • Chondroitin Sulfates / pharmacology*
  • Chondroitin Sulfates / therapeutic use
  • Cicatrix / drug therapy
  • Disease Models, Animal
  • Gliosis / metabolism
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Locomotion / drug effects
  • Macrophages / drug effects
  • Mice
  • Mice, Inbred C57BL
  • Microglia / drug effects
  • Neuronal Outgrowth / drug effects
  • Neurons / drug effects
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Recovery of Function / drug effects
  • Remyelination / drug effects
  • Spinal Cord Injuries / drug therapy*
  • Spinal Cord Injuries / etiology
  • Spinal Cord Injuries / metabolism
  • TOR Serine-Threonine Kinases / metabolism
  • rho-Associated Kinases / metabolism
  • rhoA GTP-Binding Protein / metabolism

Substances

  • Chondroitin Sulfate Proteoglycans
  • Peptides
  • Chondroitin Sulfates
  • mTOR protein, mouse
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • rho-Associated Kinases
  • RhoA protein, mouse
  • rhoA GTP-Binding Protein